Table 2.

Summary of pre-clinical outcomes of HBOT on brain function and other markers in neurodegenerative diseases

Disease	Authors	HBOT	Findings
Alzheimer’s disease-3 × Tg mice	Shapira et al., 2018	14 sessions at 2 ATA, 7 days/week, 60 min/day	Improved cognition, while reducing inflammation, plaque burden and Tau phosphorylation
Alzheimer’s disease-5 × FAD mice	Shapira et al., 2021	20 sessions at 2 ATA, 5 days/week, 60 min/day	Improved cognition and improved cerebral blood flow
Alzheimer’s disease-Aβ 25–35 injected rats	Zhang et al., 2015	20 sessions at 2 ATA, (consisted of two courses of 10 days with an interval of 3 days between two courses), 60 min/day	Improved cognitive and memory impairment in combination with Ginkgo biloba
Parkinson’s disease-6-OHDA rats	Pan et al., 2015	14 sessions at 2.4 ATA, 7 days/week, 60 min/day	Reduced apomorphine-induced turning and neuroprotection of substantia nigra’s dopaminergic neurons
Parkinson’s disease-MPTP mouse	Hsu et al., 2022	7 sessions at 2.5 ATA, 7 days/week, 60 min/day	Neuroprotection and improved motor function and increased mitochondria biogenesis signaling
Motor neuron disease-Wobbler mouse	Dave et al., 2003	30 days at 2 ATA, 60 min/day	Delaying onset via decrease in mitochondrial dysfunction